Market closed
Biomea Fusion/$BMEA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Biomea Fusion
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Ticker
$BMEA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
107
Website
Biomea Fusion Metrics
BasicAdvanced
$209M
Market cap
-
P/E ratio
-$4.00
EPS
-0.45
Beta
-
Dividend rate
Price and volume
Market cap
$209M
Beta
-0.45
52-week high
$20.21
52-week low
$3.61
Average daily volume
737K
Financial strength
Current ratio
3.395
Quick ratio
3.19
Long term debt to equity
9.049
Total debt to equity
12.593
Management effectiveness
Return on assets (TTM)
-56.38%
Return on equity (TTM)
-104.51%
Valuation
Price to book
2.75
Price to tangible book (TTM)
2.75
Price to free cash flow (TTM)
-1.834
Growth
Earnings per share change (TTM)
20.88%
3-year earnings per share growth (CAGR)
37.11%
What the Analysts think about Biomea Fusion
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Biomea Fusion stock.
Biomea Fusion Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Biomea Fusion Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Biomea Fusion News
AllArticlesVideos
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
GlobeNewsWire·3 days ago
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
GlobeNewsWire·6 days ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Biomea Fusion stock?
Biomea Fusion (BMEA) has a market cap of $209M as of December 12, 2024.
What is the P/E ratio for Biomea Fusion stock?
The price to earnings (P/E) ratio for Biomea Fusion (BMEA) stock is 0 as of December 12, 2024.
Does Biomea Fusion stock pay dividends?
No, Biomea Fusion (BMEA) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Biomea Fusion dividend payment date?
Biomea Fusion (BMEA) stock does not pay dividends to its shareholders.
What is the beta indicator for Biomea Fusion?
Biomea Fusion (BMEA) has a beta rating of -0.45. This means that it has an inverse relation to market volatility.